CCEL
Cryo-Cell International, Inc.
CCEL has a slight edge over NVO overall, supported by stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CCEL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Weak |
CCEL's revenue and cash flow are currently stable, but its profitability and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CCEL PE Valuation
CCEL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 68x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Decline | |
| -- | |
| Limited | |
| -- |
Analysts expect CCEL to return to profit, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.22 | -$0.15 |
| Q2 2026 | -$0.29 | -$0.26 |
| Q1 2026 | -$0.32 | -3300% |
| Q4 2025 | -$0.30 | -700% |
| Q3 2025 | -$0.07 | +$0.99 |
| Q2 2025 | -$0.03 | +$1.08 |
| Q1 2025 | $0.01 | +$1.17 |
| Q4 2024 | $0.05 | +$1.19 |
CCEL is still losing money, but far less than before: $0.22 per share over the past year, against $1.16 at its worst in early 2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CCEL on earnings quality, reporting a profit while its opponent remains loss making.
CCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8M | 0% |
| Q2 2026 | $7.8M | -1.9% |
| Q1 2026 | $7.7M | -3.6% |
| Q4 2025 | $7.8M | -2.3% |
| Q3 2025 | $7.8M | -3% |
| Q2 2025 | $7.9M | -1.4% |
| Q1 2025 | $8M | +1.5% |
| Q4 2024 | $8M | +1.9% |
CCEL's revenue has held roughly level: $8M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +3.8 points |
| Q2 2026 | 15% | -3.4 points |
| Q1 2026 | 10% | -3.3 points |
| Q4 2025 | -51% | -49 points |
| Q3 2025 | 24% | +7.1 points |
| Q2 2025 | 19% | +1.5 points |
| Q1 2025 | 13% | +2.8 points |
| Q4 2024 | -1.5% | +204 points |
CCEL's operating margin was 28% last quarter, up 3.8 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CCEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CCEL on profitability, with a higher operating margin.
CCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1M | -58% |
| Q2 2026 | $1.8M | +181% |
| Q1 2026 | $584.8K | -34% |
| Q4 2025 | $1.2M | -44% |
| Q3 2025 | $2.5M | +11% |
| Q2 2025 | $644.6K | +2891% |
| Q1 2025 | $892K | +$1.7M |
| Q4 2024 | $2.1M | +32% |
CCEL still generates free cash flow, though less than at its 2020 peak: $5M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.7K shares |
| 1 year | -0.1% | -8.5K shares |
| 3 years | -3.3% | -277K shares |
| 5 years | -7.2% | -627K shares |
| Available history | -4.1% | -347K shares |
CCEL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $80,883 |
| Q2 2025 | $88,619 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16,400 |
| Q2 2024 | $1.2M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CCEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CCEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.5x | High |
| Q2 2026 | 10.3x | High |
| Q1 2026 | 7.7x | High |
| Q4 2025 | 6.0x | High |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 2.0x | Healthy |
CCEL's net debt is about 6.5 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over CCEL on leverage, with a lower net debt burden relative to earnings.
CCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.8 | Neutral |
| Stochastic | 88.0 | Overbought |
CCEL's weekly RSI is 67 (neutral) and its Stochastic is 88 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CCEL PE vs Healthcare Sector
| Metric | CCEL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCEL has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.62 | 17% above |
| 20 week MA | $4.16 | 30% above |
| 50 week MA | $3.75 | 44% above |
| 100 week MA | $4.69 | 15% above |
| 200 week MA | $5.37 | 0.6% above |
CCEL has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.22 | $7.50 | +3.9% |
| 2021 | $7.50 | $12.4 | +65% |
| 2022 | $12.4 | $4.30 | -65% |
| 2023 | $4.30 | $5.75 | +34% |
| 2024 | $5.75 | $7.72 | +34% |
| 2025 | $7.72 | $3.50 | -55% |
| 2026 YTD | $3.50 | $5.40 | +54% |
CCEL has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.